Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Over 1.6 million people over State Pension age across Great Britain, including nearly 146,300 in Scotland, are set to receive ...

As per the Federal Health data, nearly 89% of older adults take prescribed drugs and more than half take four or more ...

ion.ucl.ac.uk It is chastening to reflect that although the portfolio of available drug treatments for Parkinson’s disease has multiplied, l-dopa, in its fourth decade of clinical use is still the ...